Gain Therapeutics
GANX
24 hedge funds and large institutions have $4.95M invested in Gain Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
170% more call options, than puts
Call options by funds: $54K | Put options by funds: $20K
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
1.65% more ownership
Funds ownership: 10.28% → 11.93% (+1.7%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
13% less capital invested
Capital invested by funds: $5.68M → $4.95M (-$725K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$720K |
| 2 |
GC
Greenlight Capital
New York
|
+$159K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36.5K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$32.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$56.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.3K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$15.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$27 | -6 | Closed |
|
GANX Hedge Fund Activity: Q3 2023 in Review
24 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2023, worth a combined $4.95M — down 13% from $5.68M a quarter earlier.
Fund positioning in GANX was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 9 added to existing stakes and 6 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $720K. The largest seller was Millennium Management, exiting entirely with an estimated $56.3K sold.
- 24 institutional investors held Gain Therapeutics (GANX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $4.95M of Gain Therapeutics stock for Q3 2023, down 13% quarter-over-quarter.
- 2 funds opened new Gain Therapeutics positions in Q3 2023 and 2 closed out, a net change of 0 holders.
- The largest Gain Therapeutics buyer in Q3 2023 was Royal Bank of Canada, an estimated $720K added.
- The largest Gain Therapeutics seller in Q3 2023 was Millennium Management, an estimated $56.3K sold.
Based on aggregated 13F filings for Q3 2023.